Amniotic Membrane Market - Forecast(2022 - 2027)

Soumya kalaveni

55
views

The Amniotic Membrane Market size is estimated to reach $1.15 billion by 2027 and is poised to grow at a CAGR of 7.8% over the forecast period of 2022-2027.

Amniotic Membrane Market

The amniotic membrane is an avascular fetal membrane, which lies deep down the chorion, and is usually harvested in a sterile environment, particularly from the placental tissue in the cesarean procedures. After opting for the following procedure, the elected donor is screened for transmissible diseases, following which amnion is treated with a broad spectrum of antibiotics. The amnion is made up of three layers- epithelium, basement membrane, and lastly, the stroma. Furthermore, amniotic membrane transplantation is widely used as a graft in various surgeries, making it of utmost use in the field of ophthalmology. Moreover, membrane transplantation is being used in various subspecialties. Additionally, technologies such as PROKERA are being rapidly made accessible to the world around. It is a medical device used to protect, repair, and even heal damaged surfaces of the eyes. Owing to a surge in the R&D-related activities in stem cell and regenerative medicine along with the properties of amniotic membrane in reducing pain and improving the healing process are some of the factors driving the Amniotic Membrane Industry forward in the forecast period.

Report Coverage

The report: “Amniotic Membrane Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Amniotic Membrane Market.

By Type- Cryopreserved Amniotic Membrane and Dehydrated Amniotic Membrane.
By Application- Ophthalmology, Surgical Wounds Repairment, and Others.
By End-Users- Hospitals, Ambulatory Surgical Centers, Private Clinics, and Others.
By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (the Middle East, and Africa).

Key Takeaways

Geographically, North America’s amniotic membrane market held a dominant market share in the year 2021. It is owing to an increase in the healthcare expenditure supplemented by the rising R&D investments across the new ventures. And lastly, a surge in the ASCs has aided the market hold. Moreover, Asia-Pacific is estimated to offer lucrative growth opportunities to the marketers owing to an increase in the geriatric population and their need for having eye surgeries.
An increase in the cases of ophthalmic surgeries supplemented with old age is the key market driver. However, the side effects post surgeries have impeded the market growth.
A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Amniotic Membrane Market Report.

Amniotic Membrane Market- Geography (%) for 2021

For More Details on This Report - Request for Sample

Amniotic Membrane Market Segmentation Analysis - By Type

The amniotic membrane market based on type can be further segmented into Cryopreserved Amniotic Membrane and Dehydrated Amniotic Membrane. Cryopreserved Amniotic Membrane held a dominant market share in the year 2021. The cryopreservation technique is based on slow-freezing, usually at -80 degrees, thereby also using DMEM or glycerol, to not form ice. Owing to the following technique, it retains extracellular matrix components, such as heavy-chain hyaluronic acids, growth factors, fibronectin, and collagen, all of which promote anti-inflammatory effects and healing.

Moreover, the cryopreserved amniotic membrane segment is estimated to be the fastest-growing, with a CAGR of 8.4% over the forecast period of 2022-2027. It is owing to the predominant product launches and advances being made in the following segment. The cryopreserved amniotic membrane is obtained from the C-sections, whose numbers are growing. The worldwide C-sections procedure has zoomed from 7% in 1990 to 21% in 2021, and WHO predicts for it to rise in the coming decades, thereby facilitating the overall growth of the market.

Amniotic Membrane Market Segmentation Analysis - By Application

The amniotic membrane market based on the application can be further segmented into Ophthalmology, Surgical Wounds Repairment, and Others. The ophthalmology segment held a dominant market share in the year 2021. It is owing to its properties that initiate a faster recovery time, while also substantially reducing the inflammation. Moreover, the amniotic membrane is also used to reduce scarring and post-operative eye cohesion stress. Additionally, the geriatric population is highly susceptible to having eye-related ailments, and the population of seniors in the demographic is increasing. For example, as per US CDC, the demographic demarcation of the seniors is growing, and by 2030, their segment would weigh close to 22%, which for now is 16%.

Additionally, the ophthalmology segment is estimated to be the fastest-growing, with a CAGR of 8.5% over the forecast period of 2022-2027. It is owing to a range of product innovations and discoveries stemming from the research in regenerative medicines, which will allow for better usage of amniotic membranes in the said segment.

Amniotic Membrane Market Segmentation Analysis - By Geography

The amniotic membrane market based on geography can be further segmented into North America, South America, Europe, Asia-Pacific, and the rest of the World. North America’s amniotic membrane held a dominant market share of 39% as compared to the other regions. It is owing to the region’s superior position in launching better products, which allows for the use in multiple applications. Additionally, the US government spent close to 5% or $175 billion in 2018 only for R&D in medical systems. Owing to such strategies and reimbursement policies under medical insurances, the market held a significant position.

However, Asia-Pacific is estimated to offer lucrative growth opportunities to marketers. It is owing to the surge in medical inventions, predominantly seen in the countries such as Korea, Japan, China, and India. Moreover, India saw an incremental budget allotment of 137% as compared to the previous year, to enhance the overall medical infrastructure. Owing to better policies and an improved outlook, the market is expected to grow at a steadfast pace in the projected period of 2022-2027.

Amniotic Membrane Market Drivers

The use of sutureless AMs in promoting and healing ocular surface conditions has readily aided the market growth

The use of sutureless technology has the potential to promote the overall healing process of the surface conditions which have stemmed owing to corneal scarring and people not responding to other treatments. For example, Keratitis, an inflammatory condition of the cornea which covers the pupil and iris can be created from infectious sources and non-infectious sources. In the case of the former, an antibiotic treatment course is recommended, however, in the case of the latter the keratitis can be created owing to contact lens overwear, auto-immune disease, and even dry-eye. The auto-immune keratitis most commonly occurs in patients suffering from rheumatoid arthritis. In the US, out of every 100,000 people, 71 are diagnosed with the following arthritis form, additionally, 1.5 million Americans have rheumatoid arthritis. Neurotrophic keratitis is again a serious condition, which can be caused by corneal nerve damage. Moreover, the former form is a result of a trauma or herpetic infection. Further, the following form of keratitis can be of utmost difficulty to handle. Hence, early intervention of AM can be used to facilitate faster wound healing and avoid complications such as corneal meal or even scar formation.

The growing number of ASCs has readily supplemented the market growth

ASCs or Ambulatory Surgical Centers have been growing in numbers for over a decade. In 2010, there were close to 5000 ASCs in the states of the US, however, they have now zoomed to around 10,000. The Medicare which is certified by ASCs, particularly in ophthalmology stands at the position of three, only after “orthopedic” and “pain.” Substantially, in a single specialty ASCs, a share of 25% is being kept reserved by the ophthalmology department. Since the geriatric population is more susceptible to having ocular diseases, the ASCs have bloomed. Moreover, the senior population prefers the following setup for any procedures as they are cost-sensitive, allow the patient to return on the same day, and also the chances of catching an SSIs are relatively low. Lastly, the government of the US plans to save around $22 billion by the use of ASC, under the American Rescue Plan, moreover, the Association of ASCs predict that they can help the Medicare program in saving up to $58 billion over the next decade. Owing to such parameters, the market is estimated to grow.

Amniotic Membrane Market Challenges

The post-operative challenges have been a market growth dampener

The use of AMs has been of excessive use in the medical field, particularly in, ophthalmology for more than decades, there have been cases where postoperative complications. Corneal abrasions might arise from the lid speculum, forceps, or a very aggressive application or removal of an older version of cryopreserved AM. Moreover, patients might report an increased foreign body sensation and even discomfort which can range from severe to mild. Poor Cornea-contract lens relationship can make the overall application of AM unsuccessful. If a contracting lens is too tight it can cause impingement of the limbal stem cell region, which can exacerbate issues with a healing corneal epithelium. Owing to such disadvantages, the market faces a ready market challenge.

Amniotic Membrane Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in this market. Amniotic Membrane top 10 companies include:

Amnio Technology LLC
Celularity Inc.
Human Regenerative Technologies LLC
Katena Products Inc.
MiMedx
Integra LifeSciences Corporation
Skye Biologics Inc.
Amniox Medical Inc.
Smith And Nephew
Life Cell International Pvt Ltd.

Recent Developments

In November 2021, MIMEDX demonstrated that its dehydrated human amnion chorion membrane usually outperforms the standard care in select Mohs defect reconstructions. The product- PURION, has an associated lower risk of SSIs, poor scar cosmesis, scar revision, and additional operation at the index site when compared to other incisional repairs. Mohs micrographic surgeries are increasing in number owing to an increase in the cutaneous malignancies in the aged population.
In May 2021, MIMEDX announced a collaborative agreement with Wake Forest Institute Regenerative Medicines. The collaboration focus to develop synergy between the companies shared vision of advancing the use of amniotic membranes in making regenerative medicines. Further, advance scientific evidence in support of safe and effective clinical therapies and restore quality of life for patients and is geared to further understanding product mechanisms of action and potential therapeutic targets.
In February 2020, Integra Life-Sciences Holding Corporation launched its Amnio-Excel Plus Placental Allograft Membrane. It is the latest addition to help in repairing any soft-tissue repair procedure. AmnioExcel Plus is a next-generation, thicker, tri-layer, non-side-specific allograft consisting of amnion-chorion-amnion layers that aids in creating an environment to help close complex wounds. The proprietary DryFlex processing technology preserves the inherent growth factors, cytokines, and extracellular matrix (ECM) found in native placental tissue.